Related references
Note: Only part of the references are listed.Dysregulated metabolism: A friend-to-foe skewer of macrophages
Keywan Mortezaee et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2023)
Role of the gut microbiome in chronic diseases: a narrative review
Amrita Vijay et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2022)
Immune-checkpoint inhibitors: long-term implications of toxicity
Douglas B. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
Giulia Martini et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Checkpoint inhibitor/interleukin-based combination therapy of cancer
Keywan Mortezaee et al.
CANCER MEDICINE (2022)
PD-L1 Up-Regulation in Prostate Cancer Cells by Porphyromonas gingivalis
Sabine Groeger et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)
Chieko Michikawa et al.
NEOPLASIA (2022)
Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
M. Karayama et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
R. Perets et al.
ANNALS OF ONCOLOGY (2021)
Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives
Keywan Mortezaee et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer
Keywan Mortezaee
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2021)
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Erez N. Baruch et al.
SCIENCE (2021)
Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice
Se-Hoon Lee et al.
NATURE MICROBIOLOGY (2021)
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Julianne D. Twomey et al.
AAPS JOURNAL (2021)
The impact of hypoxia on immune state in cancer
Keywan Mortezaee et al.
LIFE SCIENCES (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients
Diwakar Davar et al.
SCIENCE (2021)
Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients
Min-Woo Chung et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Jamal Majidpoor et al.
CLINICAL IMMUNOLOGY (2021)
Angiogenesis as a hallmark of solid tumors-clinical perspectives
Jamal Majidpoor et al.
CELLULAR ONCOLOGY (2021)
Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry
Iwona Kwiecien et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer
Min Jung Geum et al.
PHARMACEUTICALS (2021)
Normalization in tumor ecosystem: Opportunities and challenges
Keywan Mortezaee
CELL BIOLOGY INTERNATIONAL (2021)
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
Filippo Pederzoli et al.
EUROPEAN UROLOGY (2021)
The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges
Youssef Bouferraa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Immune checkpoint inhibitors in melanoma
Matteo S Carlino et al.
LANCET (2021)
Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
Eiko Hayase et al.
GENOME MEDICINE (2021)
Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
Geng-wei Huo et al.
OPEN MEDICINE (2021)
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2020)
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Andrea Botticelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1α and HIF-2α
Keywan Mortezaee
LIFE SCIENCES (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular mechanism of SHP2 activation by PD-1 stimulation
M. Marasco et al.
SCIENCE ADVANCES (2020)
Biostimulating Gut Microbiome with Bilberry Anthocyanin Combo to Enhance Anti-PD-L1 Efficiency against Murine Colon Cancer
Xuerun Liu et al.
MICROORGANISMS (2020)
Interaction between microbiota and immunity in health and disease
Danping Zheng et al.
CELL RESEARCH (2020)
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis
Shaily Arora et al.
CLINICAL CANCER RESEARCH (2020)
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway
Xinjian Xu et al.
FRONTIERS IN MICROBIOLOGY (2020)
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
John W. Walker et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Ashley M. Hopkins et al.
EUROPEAN UROLOGY (2020)
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
Yiannis Philippou et al.
BRITISH JOURNAL OF CANCER (2020)
Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors
Motoo Nomura et al.
JAMA NETWORK OPEN (2020)
EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
A. Sezer et al.
ANNALS OF ONCOLOGY (2020)
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
Eliran Kadosh et al.
NATURE (2020)
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy
Jumin Huang et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Andrea B. Apolo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Disruption of the redox balance with either oxidative or anti-oxidative overloading as a promising target for cancer therapy
Bagher Farhood et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Doxorubicin and Anti-PD-L1 Antibody Conjugated Gold Nanoparticles for Colorectal Cancer Photochemotherapy
Fakhrossadat Emami et al.
MOLECULAR PHARMACEUTICS (2019)
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Takeshi Tanoue et al.
NATURE (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment
Ji Lv et al.
CELL DEATH & DISEASE (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small updates cell lung cancer patients treated with nivolumab
Julia Ouaknine Krief et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma
Yi Zheng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer
E. Fiegle et al.
NEOPLASIA (2019)
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
David J. Pinato et al.
JAMA ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Haoxin Li et al.
NATURE COMMUNICATIONS (2019)
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Annika De Sousa Linhares et al.
SCIENTIFIC REPORTS (2019)
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
David B. Page et al.
NPJ BREAST CANCER (2019)
Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
Rossanna C. Pezo et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
L. Derosa et al.
ANNALS OF ONCOLOGY (2018)
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study
David M. Golombos et al.
UROLOGY (2018)
Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology
Shuji Ogino et al.
Annual Review of Pathology-Mechanisms of Disease (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Diet, Microbiota and Gut-Lung Connection
Swadha Anand et al.
FRONTIERS IN MICROBIOLOGY (2018)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang et al.
NATURE MEDICINE (2018)
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Silvia C. Formenti et al.
NATURE MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota
Mengxue Dong et al.
CELL DEATH & DISEASE (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment
Anna Louise Pouncey et al.
ECANCERMEDICALSCIENCE (2018)
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer
Brant A. Inman et al.
CLINICAL CANCER RESEARCH (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Recent advances of bispecific antibodies in solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
Kevin J. Harrington et al.
LANCET ONCOLOGY (2017)
De-novo and acquired resistance to immune checkpoint targeting
Nicholas L. Syn et al.
LANCET ONCOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil et al.
PLOS ONE (2017)
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
Arthur E. Frankel et al.
NEOPLASIA (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Microbiota: a key orchestrator of cancer therapy
Soumen Roy et al.
NATURE REVIEWS CANCER (2017)
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Takeru Asano et al.
BLOOD (2017)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
Jonathan M. Pitt et al.
CANCER RESEARCH (2016)
Microbiome and Anticancer Immunosurveillance
Laurence Zitvogel et al.
CELL (2016)
Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects
Romain Daillere et al.
IMMUNITY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Basics of PD-1 in self-tolerance, infection, and cancer immunity
Shunsuke Chikuma
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2016)
The microbiota in adaptive immune homeostasis and disease
Kenya Honda et al.
NATURE (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions
Linda S. Zhang et al.
GENOME MEDICINE (2016)
Characterization of the microbiome of nipple aspirate fluid of breast cancer survivors
Alfred A. Chan et al.
SCIENTIFIC REPORTS (2016)
Immunotherapy for head and neck squamous cell carcinoma
Thorsten Fuereder
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2016)
PD-1/PD-L1 inhibitors
Joel Sunshine et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Salmonella induces PD-L1 expression in B cells
Marcela Lopez-Medina et al.
IMMUNOLOGY LETTERS (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Cancer and the gut microbiota: An unexpected link
Laurence Zitvogel et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
Vassiliki A. Boussiotis et al.
CANCER JOURNAL (2014)
The Human Gut Microbiome as a Screening Tool for Colorectal Cancer
Joseph P. Zackular et al.
CANCER PREVENTION RESEARCH (2014)
Role of the Microbiota in Immunity and Inflammation
Yasmine Belkaid et al.
CELL (2014)
Microbes, Microbiota, and Colon Cancer
Cynthia L. Sears et al.
CELL HOST & MICROBE (2014)
Differences in Gastric Mucosal Microbiota Profiling in Patients with Chronic Gastritis, Intestinal Metaplasia, and Gastric Cancer Using Pyrosequencing Methods
Chang Soo Eun et al.
HELICOBACTER (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Diet rapidly and reproducibly alters the human gut microbiome
Lawrence A. David et al.
NATURE (2014)
Lung microbiota promotes tolerance to allergens in neonates via PD-L1
Eva S. Gollwitzer et al.
NATURE MEDICINE (2014)
PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
Dawn E. Dolan et al.
CANCER CONTROL (2014)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2013)
Fecal microbiota transplantation: past, present and future
Olga C. Aroniadis et al.
CURRENT OPINION IN GASTROENTEROLOGY (2013)
Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8
Masahide Shinnoh et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Xiaoxiao Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Noriho Iida et al.
SCIENCE (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Sophie Viaud et al.
SCIENCE (2013)
PD-1 as a potential target in cancer therapy
David F. McDermott et al.
CANCER MEDICINE (2013)
Microbial Translocation Across the GI Tract
Jason M. Brenchley et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
The Impact of the Gut Microbiota on Human Health: An Integrative View
Jose C. Clemente et al.
CELL (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Human gut microbiome viewed across age and geography
Tanya Yatsunenko et al.
NATURE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Overall Survival and PD-L1 Expression in Metastasized Malignant Melanoma
Jules Gadiot et al.
CANCER (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Qiang Gao et al.
CLINICAL CANCER RESEARCH (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls
Johan Dicksved et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon
Markus Waldecker et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2008)
The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat
Lieve Desbonnet et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2008)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression
Henry Radziewicz et al.
JOURNAL OF VIROLOGY (2007)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation
Harmjan Kuipers et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Ecological and evolutionary forces shaping microbial diversity in the human intestine
RE Ley et al.
CELL (2006)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
Butyrate specifically down-regulates Salmonella pathogenicity island 1 gene expression
I Gantois et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders
ES James et al.
GENES AND IMMUNITY (2005)
Host-bacterial mutualism in the human intestine
F Bäckhed et al.
SCIENCE (2005)
Structural and functional analysis of the costimulatory receptor programmed death-1
XW Zhang et al.
IMMUNITY (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation:: relevance for the immune modulatory effect in multiple sclerosis
B Schreiner et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
BG Neel et al.
TRENDS IN BIOCHEMICAL SCIENCES (2003)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
